Expression of epidermal growth factor variant III (EGFRvIII) in pediatric diffuse intrinsic pontine gliomas

@article{Li2012ExpressionOE,
  title={Expression of epidermal growth factor variant III (EGFRvIII) in pediatric diffuse intrinsic pontine gliomas},
  author={Gordon Li and Siddhartha S Mitra and Michelle Monje and Kristy N. Henrich and Charles D. Bangs and Ryan T. Nitta and Albert J. Wong},
  journal={Journal of Neuro-Oncology},
  year={2012},
  volume={108},
  pages={395-402}
}
Despite numerous clinical trials over the past 2 decades, the overall survival for children diagnosed with diffuse intrinsic pontine glioma (DIPG) remains 9–10 months. Radiation therapy is the only treatment with proven effect and novel therapies are needed. Epidermal growth factor receptor variant III (EGFRvIII) is the most common variant of the epidermal growth factor receptor and is expressed in many tumor types but is rarely found in normal tissue. A peptide vaccine targeting EGFRvIII is… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 26 references

Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification

AJ Wong
Proc Natl Acad Sci USA • 1987
View 10 Excerpts
Highly Influenced

Hedgehog-responsive candidate cell of origin for diffuse intrinsic pontine glioma.

Proceedings of the National Academy of Sciences of the United States of America • 2011
View 2 Excerpts

EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2009
View 1 Excerpt

Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines

RJ Schmittling
J Immunol Methods • 2008

EGFR antagonists in cancer treatment.

The New England journal of medicine • 2008
View 1 Excerpt

Effect of EGFRvIIItargeted vaccine ( CDX110 ) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM

JH Sampson
2008

Similar Papers

Loading similar papers…